Mereo BioPharma Group Stock
Mereo BioPharma Group plc
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- CEO
- Denise Vera Scots-Knight
- Employees
- 39
- Market cap
- $48 M
- IPO
- 24/04/2019
Mereo BioPharma Group plc, a London-based biopharmaceutical firm established in 2015, specializes in developing and commercializing innovative therapies for oncology and rare conditions. Operating both in the United Kingdom and internationally, the company boasts a diverse product pipeline. Its primary oncology asset,…
Mereo BioPharma Group stock: price history
1D
-2.0%
1W
-13.4%
1M
+13.9%
6M
-10.0%
YTD
-27.3%
1Y
-84.9%
2Y
-93.3%
5Y
-86.1%
10Y
–
Next earnings date
Next earnings date
09/11/2026 (in 23 days)
Volatility around earnings
~39% weaker price swings than usual
Ask the agents about Mereo BioPharma Group
Analyst assessment of Mereo BioPharma Group
PRICE TARGET LOW
US$0.50
CONSENSUS
US$3.25
MEDIAN
US$2.50
PRICE TARGET HIGH
US$8.00
0
STRONG BUY
5
BUY
2
HOLD
1
SELL
0
STRONG SELL
8
TOTAL · Buy
As of: 19/08/2026
Mereo BioPharma Group stock metrics
P/E
-1.66
P/B
1.7
EV/EBITDA
-0.59
RETURN ON EQUITY
-24.4%
NET MARGIN
0.0%
DEBT/EQUITY
0.04
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
100.0%
FLOAT SHARES
159,618,609
AVG. DAILY VOLUME (30D)
1,711,226
Institutional holders
Comparable stocks
Frequently asked questions about Mereo BioPharma Group stock
What does Mereo BioPharma Group do?
Mereo BioPharma Group plc is a company in the Healthcare sector, Biotechnology industry, headquartered in United Kingdom.
The CEO is Denise Vera Scots-Knight, the company employs around 39 people.
The IPO was on 24/04/2019; the stock trades on NASDAQ under the ticker MREO.
What do analysts say about Mereo BioPharma Group stock?
8 analysts rate the stock, the consensus is Buy (as of 19/08/2026).
The average price target is US$3.25, ranging from US$0.50 to US$8.00, with a median of US$2.50.
This is an external assessment, not a statement by Market Jury.
When does Mereo BioPharma Group report next?
The next earnings date is 09/11/2026.
Around past earnings, price swings were roughly -39% stronger than usual.
Does Mereo BioPharma Group pay a dividend?
No, Mereo BioPharma Group currently does not pay a dividend.
Which stocks are comparable to Mereo BioPharma Group?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.
How can I get Mereo BioPharma Group stock analyzed?
Clicking "Analyze stock" lets five strategies assess Mereo BioPharma Group against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.